These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29759802)

  • 21. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
    Chen J; Liu T; Sun Q; Jin T
    Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Xue Y; Li G; Xie T; Xu H; Xu T; Li Z; Zhu L; Li X; Li Z; Xiong W
    Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3097-3106. PubMed ID: 37079074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.
    Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX
    JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone.
    Wu JS; Tsai YC; Jian JJ; Chen HH; Horng CF; Cheng SH
    Head Neck; 2018 Sep; 40(9):2070-2077. PubMed ID: 29756398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.
    Jouin A; Helfre S; Bolle S; Claude L; Laprie A; Bogart E; Vigneron C; Potet H; Ducassou A; Claren A; Riet FG; Castex MP; Faure-Conter C; Fresneau B; Defachelles AS; Orbach D
    Strahlenther Onkol; 2019 Jun; 195(6):504-516. PubMed ID: 30963203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.
    You R; Cao YS; Huang PY; Chen L; Yang Q; Liu YP; Zou X; Zhang YN; Jiang R; Zhang MX; Duan CY; Lin AH; Hong MH; Chen MY
    Theranostics; 2017; 7(19):4825-4835. PubMed ID: 29187906
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
    Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
    Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
    Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
    Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
    Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
    Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: A retrospective study.
    Katano A; Takahashi W; Yamashita H; Yamamoto K; Ando M; Yoshida M; Saito Y; Abe O; Nakagawa K
    Medicine (Baltimore); 2018 May; 97(18):e0502. PubMed ID: 29718841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.